Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Sheila Annie Peters

potential of drugs in vivo in humans. Pharmaceutical Research 23 (1): 56–69. https://doi.org/10.1007/s11095‐005‐8812‐5.

      34 Riley, R.J., Grime, K., and Weaver, R. (2007). Time‐dependent CYP inhibition. Expert Opinion on Drug Metabolism and Toxicology: 51–66. https://doi.org/10.1517/17425255.3.1.51.

      35 Shitara, Y. et al. (2009). Long‐lasting inhibition of the transporter‐mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metabolism and Disposition 37 (6): 1172–1178. https://doi.org/10.1124/dmd.108.025544.

      36 Silverman, R.B. and Hiebert, C.K. (1988). Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1‐phenylcyclopropylamine, 1‐benzylcyclopropylamine, and N‐cyclopropyl‐α‐methylbenzylamine. Biochemistry 27 (22): 8448–8453. https://doi.org/10.1021/bi00422a023.

      37 Sinz, M. et al. (2006). Evaluation of 170 Xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Current Drug Metabolism 7 (4): 375–388. https://doi.org/10.2174/138920006776873535.

      38 Somogyi, A. et al. (1987). Reduction of metformin renal tubular secretion by cimetidine in man. British Journal of Clinical Pharmacology 23 (5): 545–551. https://doi.org/10.1111/j.1365‐2125.1987.tb03090.x.

      39 USFDA (2020a). Clinical drug interaction studies Cytochrome P450 enzyme‐ and transporter‐mediated drug interactions ‐ Guidance for industry. Silver Spring, January 2020. https://www.fda.gov/media/134581/download.

      40 USFDA (2020b). In vitro drug interaction studies: Cytochrome p450 enzyme‐ and transporter‐mediated drug interactions Guidance for industry. Silver Spring, January 2020. https://www.fda.gov/media/134582/download.

      41 USFDA (2020c). Drug-drug interaction assessment for therapeutic proteins. Guidance for Industry. Silver Spring, August 2020. https://www.fda.gov/media/140909/download.

      42 Venkatakrishnan, K. et al. (2005). Drug metabolism and drug interactions: application and clinical value of in vitro models. Current Drug Metabolism 4 (5): 423–459. https://doi.org/10.2174/1389200033489361.

      43 Venkatakrishnan, K. and Obach, R.S. (2007). Drug‐drug interactions via mechanism‐based cytochrome P450 inactivation: Points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Current Drug Metabolism 8 (5): 449–462. https://doi.org/10.2174/138920007780866861.

      44 Watanabe, A. et al. (2007). Risk assessment for drug‐drug interaction caused by metabolism‐based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metabolism and Disposition 35 (7): 1232–1238. https://doi.org/10.1124/dmd.107.015016.

      45 Wu, K.C. and Lin, C.J. (2019). The regulation of drug‐metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age‐related disorders. Journal of Food and Drug Analysis 27 (1): 48–59. https://doi.org/10.1016/j.jfda.2018.11.005.

      46 Yang, J. et al. (2008). Cytochrome P450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current Drug Metabolism 9 (5): 384–393. https://doi.org/10.2174/138920008784746382.

      47 Yung‐Chi, C. and Prusoff, W.H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 22 (23): 3099–3108. https://doi.org/10.1016/0006‐2952(73)90196‐2.

      48 Zhang, X. et al. (2009). Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metabolism and Disposition 37 (8): 1587–1597. https://doi.org/10.1124/dmd.109.026658.